Deletions of the INK4A gene in superficial bladder tumors: Association with recurrence

American Journal of Pathology

Volumn 155, Issue 1, 1999, Pages 105-113

  Orlow, Irene ^a   LaRue, Helene ^b   Osman, Iman ^a   Lacombe, Louis ^b   Moore, Lynne ^b   Rabbani, Farhang ^a   Meyer, François ^b   Fradet, Yves ^b   Cordon Cardo, Carlos ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN P16; PROTEIN P19; UNCLASSIFIED DRUG;

ARTICLE; BLADDER TUMOR; CANCER SURVIVAL; CHROMOSOME 9P; DNA METHYLATION; EXON; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PHENOTYPE; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; PROMOTER REGION; RECURRENT DISEASE; TUMOR VOLUME;

EID: 0033031043     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65105-X     Document Type: Article

References (45)

1. Hunter T, Pines J: Cyclins and cancer. II. Cyclin D and CDK inhibitors come of age. Cell 1994, 79:573-582
2. Cordon-Cardo C: Mutation of cell cycle regulators: biological and clinical implications for human neoplasias. Am J Pathol 1995, 147: 545-560
3. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366:704-707
4. Kamb A, Gruis NA, Weaver Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Stockert E, Day RS 3rd, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264:436-440
5. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA: Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368:753-756
6. Hannon GJ, Beach D: p15 INK4B is a potential effector of TGFβ induced cell cycle arrest. Nature 1994, 371:257-261
7. Quelle DE, Zindy F, Ashmun RA, Sherr CJ: Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 1995, 83:993-1000
8. Duro D, Bernard O, Delia Valle V, Berger R, Larsen CJ: A new type of p16INK4/MTS1 gene transcript expressed in B-cell malignancies. Oncogene 1995, 11:21-29
9. Mao L, Merlo A, Bedi G, Shapiro GI, Edwards CD, Rollins BJ, Sidransky D: A novel p16INK4A transcript. Cancer Res 1995, 55:2995-2997
10. Stone S, Jiang P, Dayananth P, Tavtigian SV, Katcher H, Parry D, Peters G, Kamb A: Complex structure and regulation of the P16 (MTS1) locus. Cancer Res 1995, 55:2988-2994
11. Arf, interacts with MDM2 and neutralizes MDM2's inhibition of p53. Cell 1998, 92: 713-723
12. Zhang Y, Xiong Y, Yarbrough WG: ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998, 92:725-734
13. Jen J, Harper JW, Bigner SH, Bigner DD, Papadopoulos N, Markowitz S, Willson JK, Kinzler KW, Vogelstein B: Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994, 54:6353-6358
14. Spruck CH III, Gonzalez-Zulueta M, Shibata A, Simoneau AR, Lin MF, Gonzales F, Tsai YC, Jones PA: p16 gene in uncultured tumours. Nature 1994, 370:183-184
15. Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang Z-F, Beach D, Cordon-Cardo C: Deletion of the p16 and p15 genes in human bladder tumors. J Natl Cancer Inst 1995, 87:1524-1529
16. Reed AL, Califano J, Cairns P, Westra WH, Jones RM, Koch W, Ahrendt S, Eby Y, Sewell D, Nawroz H, Bartek J, Sidransky D: High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res 1996, 56:3630-3633
17. Washimi O, Nagatake M, Osada H, Ueda R, Koshikawa T, Seki T, Takahashi T, Takahashi T: In vivo ocurrence of p16 (MTS1) and p15 (MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 1995, 55:514-517
18. Hussussian CJ, Struewing JP, Goldstein AM, Higgins PA, Ally DS, Sheahan MD, Clark WH Jr. Tucker MA, Dracopoli NC: Germline p16 mutations in familial melanoma. Nat Genet 1994, 8:15-21
19. Gruis NA, van der Velden PA, Sandkuijl LA, Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W, Frants RR Homozygotes for CDKN2 (p16) germline mutation in Dutch familial melanoma kindreds. Nat Genet 1995, 10:351-353
20. Goldstein AM, Fraser MC, Struewing JP, Hussussian CJ, Ranade K, Zametkin DP, Fontaine LS, Organic SM, Dracopoli NC, Clark WH Jr, Tucker MA: Increased risk of pancreatic cancer in melanoma-prone kindreds with p16INK4 mutations. N Engl J Med 1995, 333:970-974
21. Serrano M, Lee H.-W, Chin L, Cordon-Cardo C, Beach D, DePinho R: Role of the INK4a locus in tumor suppression and cell mortality. Cell 1996, 85:27-37
22. ARF. Cell 1997, 91:649-659
23. González-Zulueta M, Bender CM, Yang AS, Nguyen T, Beart RW, Van Tornout JM, Jones PA: Methylation of the 5′ CpG island of the p16/ CDKN2 tumor suppressor gene in normal and transformed human tissues correlates with gene silencing. Cancer Res 1995, 55:4531-4535
24. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger P, Baylin SB, Sidransky D: 5′ CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2/Mts1 in human cancers. Nat Med 1995, 1:686-692
25. Allard P, Fradet Y, Tetu B, Bernard P, Quebec Urology Research Group: Tumor-associated antigens as prognostic factors for recurrence in 382 patients with primary transitional cell carcinoma of the bladder. Clin Cancer Res 1995, 1:1195-1202
26. LaRue H, Simoneau M, Fradet Y: Human papillomavirus in transitional cell carcinoma of the urinary bladder. Clin Cancer Res 1995, 1:435-440
27. Chin L, Pomerantz J, Polsky D, Jacobson M, Cohen C, Cordon-Cardo C, Horner JW II, DePinho RA: Cooperative effects of Ink4a and ras in melanoma susceptibility in vivo. Genes Dev 1997, 11:2822-2834
28. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB: Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996, 93:9821-9826
29. Metha CR, Patel NR: A network algorithm for performing Fisher's Exact test r × c contingency tables. J Am Stat Assoc 1983, 78: 427-434
30. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958, 53:457-481
31. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV: Design and analysis of randomized trials requiring prolonged observation of each patient. Br J Cancer 1977, 35:1-39
32. SAS/STAT users guide, version 6. Cary, NC, SAS institute, Inc., 1990
33. Cox DR: Regression models and life tables. J R Stat Soc B 1972, 34:187-22C
34. Cox DR: Partial likelihood. Biometrika 1975, 62:269-276
35. Liggett WH Jr, Sidransky D: Role of the p16 tumor suppressor gene in cancer. J Clin Oncol 1998, 16:1197-1206
36. Knudsor, AG Jr: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci USA 1971, 68:820-823
37. Hara E, Smith R, Parry D, Tahara H, Stone S, Peters G: Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol 1996, 16:859-867
38. Kratzke RA, Greatens TM, Rubins JB, Maddaus MA, Niewoehner DE, Niehans GA, Geradts J: Rb and p16INK4a expression in resected non-small cell lung tumors. Cancer 1996, 56:3415-3420
39. Lukas J, Parry D, Aagaard L, Mann DJ, Bartkova J, Strauss M, Peters G, Bartek J: Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature 1995, 375:503-506
40. Lonardo F, Ueda T, Huvos AG, Healey J, Ladanyi M: p53 and MDM2 alterations in osteosarcomas: correlation with clinicopathologic features and proliferative rate. Cancer 1997, 79:1541-1547
41. Sarkis AS, Dalbagni G, Cordon-Cardo C, Zhang ZF, Sheinfeld J, Fair WR, Herr HW, Reuter VE: Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression J Natl Cancer Inst 1993, 85:53-59
42. Lianes P, Orlow I, Zhang ZF, Oliva MR, Sarkis AS, Reuter VE, Cordon-Cardo C: Altered patterns of MDM2 and TP53 expression in human bladder cancer. J Natl Cancer Inst 1994, 86:1325-1330
43. Williams BO, Remington L, Albert DM, Mukai S, Bronson, RT, Jacks T: Cooperative tumorigenic effects of germline mutations in Rb and p53. Nat Gen 1994, 7:480-484
44. Cordon-Cardo C, Zhang Z-F, Dalbagni G, Drobnjak M, Charytonowicz E, Hu S-X, Xu H-J, Reuter VE, Benedict WF: Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors. Cancer Res 1997, 57:1217-1221
45. Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, Hu SX, Xu HJ, Groshen S, Taylor CR, Skinner DG, Benedict WF: Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998, 58: 1090-1094